home / stock / evotf / evotf short
Short Information | Evotec Ag Ord (OTCMKTS:EVOTF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 4,963 |
Total Actual Volume | 18,628 |
Short Trends | |
---|---|
Cover Days | 3 |
Short Days | 15 |
No Change Days | 2 |
Averages | |
---|---|
Average Short Volume | 248 |
Average Short Percentage | 76.38% |
Is there a EVOTF Short Squeeze or Breakout about to happen?
See the EVOTF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-24-2024 | $10.44 | $10.18 | $10.44 | $10.18 | 600 | 100 | 16.67% |
03-05-2024 | $13.93 | $13.83 | $13.93 | $13.83 | 200 | 100 | 50% |
02-05-2024 | $14.5 | $14.41 | $14.5 | $14.41 | 4,545 | 2,545 | 56% |
01-17-2024 | $16 | $16 | $16 | $16 | 250 | 100 | 40% |
01-04-2024 | $0 | $21.68 | $0 | $0 | 10,027 | 27 | 0.27% |
12-29-2023 | $23.97 | $24.61 | $24.61 | $23.97 | 300 | 300 | 100% |
10-23-2023 | $0 | $18 | $0 | $0 | 70 | 70 | 100% |
10-13-2023 | $18 | $18 | $18 | $18 | 100 | 100 | 100% |
10-02-2023 | $0 | $19.8 | $0 | $0 | 50 | 50 | 100% |
09-21-2023 | $20.73 | $19.8 | $20.73 | $19.8 | 300 | 100 | 33.33% |
09-01-2023 | $0 | $24.33 | $0 | $0 | 25 | 25 | 100% |
08-22-2023 | $0 | $24.33 | $0 | $0 | 20 | 20 | 100% |
08-17-2023 | $0 | $24.33 | $0 | $0 | 10 | 10 | 100% |
08-10-2023 | $0 | $24.33 | $0 | $0 | 20 | 20 | 100% |
07-27-2023 | $25.48 | $23.43 | $25.48 | $23.43 | 1,110 | 400 | 36.04% |
07-11-2023 | $23.37 | $23.37 | $23.37 | $23.37 | 105 | 100 | 95.24% |
06-26-2023 | $0 | $23.6 | $0 | $0 | 5 | 5 | 100% |
06-16-2023 | $23.6 | $23.6 | $23.6 | $23.6 | 690 | 690 | 100% |
06-12-2023 | $0 | $25.13 | $0 | $0 | 1 | 1 | 100% |
06-08-2023 | $25.13 | $25.13 | $25.13 | $25.13 | 200 | 200 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Just - Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD's Manufacturing Optimization Program Manufacturing solution includes seamless integration of accelerated mAb drug development into the overall Manufacturing Optimiz...
Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research HAMBURG, GERMANY / ACCESSWIRE / June 12, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/T...
Most agenda items adopted with great majority Annual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario Polywka HAMBURG, GERMANY / ACCESSWIRE / June 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDA...